Nektar Therapeutics (NKTR) to Release Earnings on Monday

Nektar Therapeutics (NASDAQ:NKTR) will likely be releasing its earnings data before the market opens on Monday, March 3rd. Analysts expect Nektar Therapeutics to post earnings of ($0.18) per share and revenue of $36.65 million for the quarter.

Nektar Therapeutics Stock Down 2.6 %

NKTR stock opened at $0.93 on Monday. The firm has a market cap of $171.95 million, a PE ratio of -1.11 and a beta of 0.58. The business has a 50 day moving average of $0.92 and a 200-day moving average of $1.12. Nektar Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.93.

Insiders Place Their Bets

In related news, insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the sale, the insider now owns 326,904 shares of the company’s stock, valued at approximately $307,289.76. This represents a 13.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the sale, the insider now directly owns 351,892 shares in the company, valued at $316,702.80. This trade represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 165,586 shares of company stock worth $159,990 over the last quarter. 3.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NKTR shares. B. Riley initiated coverage on Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Monday, January 13th. Finally, Piper Sandler started coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 target price for the company. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.